Patrick Michael Murphy net worth and biography

Patrick Murphy Biography and Net Worth

EVP of DexCom

Patrick Murphy is Executive Vice President, Chief Legal Officer at Dexcom.

Patrick assumed the role of Executive Vice President, Chief Legal Officer in January 2021. In this role, he leads the global Legal function.

Since joining Dexcom in 2011, Patrick has held various leadership roles, including Senior Vice President, General Counsel and Chief Compliance Officer, Vice President, General Counsel and Chief Compliance Officer, and Vice President of Legal Affairs and Assistant General Counsel.

Prior to Dexcom, Patrick was a partner at the law firm of Stradling Yocca Carlson & Rauth, where he specialized in corporate finance, mergers and acquisitions and general corporate matters.

Patrick received a Bachelor of Science degree from the Truman State University, and a Juris Doctorate from the St. Louis University School of Law. He is a member of the State Bar of California.

What is Patrick Michael Murphy's net worth?: The estimated net worth of Patrick Michael Murphy is at least $2.83 million as of December 2nd, 2024. Mr. Murphy owns 35,327 shares of DexCom stock worth more than $2,827,573 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Murphy may own. Learn More about Patrick Michael Murphy's net worth.
How do I contact Patrick Michael Murphy?: The corporate mailing address for Mr. Murphy and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Patrick Michael Murphy's contact information.
Has Patrick Michael Murphy been buying or selling shares of DexCom?: Patrick Michael Murphy has not been actively trading shares of DexCom in the last ninety days. Most recently, Patrick Michael Murphy sold 500 shares of the business's stock in a transaction on Thursday, August 26th. The shares were sold at an average price of $517.24, for a transaction totalling $258,620.00. Learn More on Patrick Michael Murphy's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 24 times. They sold a total of 248,077 shares worth more than $32,452,099.04. The most recent insider tranaction occured on November, 20th when EVP Sadie Stern sold 4,259 shares worth more than $318,275.07. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 11/20/2024.

Patrick Michael Murphy Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/26/2021	Sell	500	$517.24	$258,620.00
7/26/2021	Sell	500	$458.79	$229,395.00
6/28/2021	Sell	500	$431.49	$215,745.00
5/26/2021	Sell	500	$350.00	$175,000.00
4/26/2021	Sell	500	$415.83	$207,915.00
3/26/2021	Sell	500	$350.00	$175,000.00
2/26/2021	Sell	500	$396.79	$198,395.00
1/27/2021	Sell	500	$359.70	$179,850.00
12/28/2020	Sell	500	$355.39	$177,695.00
12/1/2020	Sell	6,154	$325.00	$2,000,050.00
8/10/2020	Sell	500	$439.31	$219,655.00
7/9/2020	Sell	500	$435.80	$217,900.00
6/9/2020	Sell	500	$375.36	$187,680.00
5/11/2020	Sell	500	$404.05	$202,025.00
4/9/2020	Sell	500	$259.95	$129,975.00
3/9/2020	Sell	500	$261.00	$130,500.00
2/10/2020	Sell	500	$240.59	$120,295.00
1/9/2020	Sell	500	$235.01	$117,505.00
12/9/2019	Sell	5,518	$224.42	$1,238,349.56
6/10/2019	Sell	400	$127.03	$50,812.00
5/10/2019	Sell	400	$116.92	$46,768.00
4/10/2019	Sell	400	$115.05	$46,020.00
3/8/2019	Sell	400	$141.56	$56,624.00
2/8/2019	Sell	400	$142.76	$57,104.00
1/10/2019	Sell	400	$138.75	$55,500.00
12/10/2018	Sell	400	$121.90	$48,760.00
10/10/2018	Sell	400	$122.20	$48,880.00
9/10/2018	Sell	2,372	$143.69	$340,832.68
8/10/2018	Sell	12,500	$124.18	$1,552,250.00

Patrick Michael Murphy Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $80.04

$75.47

$81.51

50 Day Range

MA: $74.53

$67.10

$81.01

2 Week Range

Now: $80.04

$62.34

$142.00

Volume

11,494,120 shs

Average Volume

3,910,878 shs

Market Capitalization

$31.26 billion

P/E Ratio

47.93

Dividend Yield

N/A

Beta

1.12

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.